GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Interest Coverage

BOLD (Boundless Bio) Interest Coverage : No Debt (1) (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Boundless Bio's Operating Income for the three months ended in Jun. 2024 was $-19.39 Mil. Boundless Bio's Interest Expense for the three months ended in Jun. 2024 was $0.00 Mil. Boundless Bio has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Boundless Bio Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Boundless Bio's Interest Coverage or its related term are showing as below:


BOLD's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 134.78
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Boundless Bio Interest Coverage Historical Data

The historical data trend for Boundless Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Boundless Bio Interest Coverage Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Interest Coverage
No Debt N/A No Debt

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A No Debt No Debt No Debt

Competitive Comparison of Boundless Bio's Interest Coverage

For the Biotechnology subindustry, Boundless Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boundless Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Interest Coverage falls into.



Boundless Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Boundless Bio's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Boundless Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-54.80 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Boundless Bio had no debt (1).

Boundless Bio's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Here, for the three months ended in Jun. 2024, Boundless Bio's Interest Expense was $0.00 Mil. Its Operating Income was $-19.39 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Boundless Bio had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Boundless Bio  (NAS:BOLD) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Boundless Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.